Imunon, Inc.
CLSN
株式のランク
#34963
Imunon, Inc. is a biotechnology firm in the clinical development stage,... Imunon, Inc. is a biotechnology firm in the clinical development stage, dedicated to innovating and commercializing DNA-centric immunotherapies, vaccines, and targeted chemotherapy solutions. Its primary pipeline assets include GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a unique formulation of doxorubicin encapsulated in heat-activated liposomes, currently being assessed for a variety of cancer indications. Furthermore, the company is advancing two early-phase platform technologies aimed at developing nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA treatments. Established in 1982, Imunon, Inc. maintains its operational base in Lawrenceville, New Jersey.
株価
$1.96
最終同期: 2022-09-20
時価総額
$4.46M
変化（1日）
0.00%
変化（1年）
122.70%
国
US
取引 Imunon, Inc. (CLSN)
カテゴリー
Healthcare
の時価総額 Imunon, Inc.(CLSN)
時価総額: $4.46M
October 2026時点で、Imunon, Inc. の時価総額は $4.46M です。これは、当社のデータによると、Imunon, Inc. が世界で34963rd番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Imunon, Inc. の時価総額の履歴（2018 から 2026 まで）
